This study is a single arm Phase II pilot trial. Patients enrolled on the trial will undergo
implantation of high activity iodine-125 seeds into their pituitary adenoma. The tumor
response to treatment will be monitored as well as change in visual fields, associated
adverse effects, progression free survival and patient reported outcomes.